Beijing’s BeiGene will collaborate with Cancer Genetics of New Jersey, a company that develops molecular markers and diagnostics to advance precision medicine in oncology. Cancer Genetics will provide central lab support for BeiGene’s clinical trials. It will also identify patient populations that respond to BeiGene’s four clinical-stage drug candidates, and it will suggest immunotherapies developed by other biopharmas that may complement BeiGene’s own candidates in joint-drug regimens.
